27819344|t|Anti-tumor activity of SL4 against breast cancer cells: induction of G2/M arrest through modulation of the MAPK -dependent p21 signaling pathway
27819344|a|SL4, a chalcone -based compound, has been shown to retard tumor invasion and angiogenesis by suppressing HIF1 activity and to induce apoptosis by promoting ROS release. Here, we report that SL4 is able to inhibit the proliferation of different types of breast cancer cell in vitro and in vivo by inducing G2/M cell cycle arrest. Our results showed that SL4 exhibited strong anti-proliferative activity in several human breast cancer cell lines, with IC50 values lower than 1.3 μM. Further studies indicated that SL4 induced G2/M arrest in these cell lines. Mechanistically, SL4 reduces the expression of cyclin A2 and cdc25C and decreases the activity of the cdc2 / cyclin B1 complex. Notably, SL4 treatment resulted in an obvious increase in p21 mRNA and protein levels through activation of MAPK signaling pathways, but not the TGF-β pathway. SP600125 and PD98059, specific inhibitors of JNK kinase and ERK kinase, significantly blocked the SL4 - induced G2/M phase arrest and upregulation of p21. Furthermore, SL4 suppressed the growth of established breast tumors in nude mice through upregulation of p21 and downregulation of cdc25C, and displayed a good safety profile. Taken together, these findings demonstrate the potential value of SL4 as a novel multi-target anti-tumor drug candidate.
27819344	0	19	Anti-tumor activity	T038	UMLS:C1516031
27819344	23	26	SL4	T103	UMLS:C4278992
27819344	35	54	breast cancer cells	T017	UMLS:C1512505
27819344	69	80	G2/M arrest	T038	UMLS:C1517345
27819344	107	111	MAPK	T103	UMLS:C0752312
27819344	123	126	p21	T103	UMLS:C0288472
27819344	127	144	signaling pathway	T038	UMLS:C0037083
27819344	145	148	SL4	T103	UMLS:C4278992
27819344	152	160	chalcone	T103	UMLS:C0007935
27819344	168	176	compound	T103	UMLS:C1706082
27819344	203	217	tumor invasion	T033	UMLS:C1269955
27819344	222	234	angiogenesis	T038	UMLS:C1519670
27819344	250	254	HIF1	T103	UMLS:C0215848
27819344	278	287	apoptosis	T038	UMLS:C0162638
27819344	301	304	ROS	T103	UMLS:C0162772
27819344	323	329	report	T170	UMLS:C0684224
27819344	335	338	SL4	T103	UMLS:C4278992
27819344	362	375	proliferation	T038	UMLS:C0596290
27819344	398	416	breast cancer cell	T017	UMLS:C1512505
27819344	430	437	in vivo	T082	UMLS:C1515655
27819344	450	472	G2/M cell cycle arrest	T038	UMLS:C1517345
27819344	498	501	SL4	T103	UMLS:C4278992
27819344	519	537	anti-proliferative	T103	UMLS:C0003392
27819344	558	563	human	T204	UMLS:C0086418
27819344	564	577	breast cancer	T038	UMLS:C0678222
27819344	578	588	cell lines	T017	UMLS:C0085983
27819344	634	641	studies	T062	UMLS:C2603343
27819344	642	651	indicated	T033	UMLS:C1444656
27819344	657	660	SL4	T103	UMLS:C4278992
27819344	669	680	G2/M arrest	T038	UMLS:C1517345
27819344	690	700	cell lines	T017	UMLS:C0085983
27819344	719	722	SL4	T103	UMLS:C4278992
27819344	735	745	expression	T038	UMLS:C0017262
27819344	749	758	cyclin A2	T103	UMLS:C0297674
27819344	763	769	cdc25C	T103	UMLS:C0213045
27819344	804	808	cdc2	T103	UMLS:C0080054
27819344	811	820	cyclin B1	T103	UMLS:C0385333
27819344	821	828	complex	T103	UMLS:C1704241
27819344	839	842	SL4	T103	UMLS:C4278992
27819344	843	852	treatment	T058	UMLS:C1533734
27819344	888	891	p21	T017	UMLS:C0249197
27819344	892	896	mRNA	T103	UMLS:C0035696
27819344	901	908	protein	T103	UMLS:C0033684
27819344	924	934	activation	T038	UMLS:C2259058
27819344	938	961	MAPK signaling pathways	T038	UMLS:C1518102
27819344	975	988	TGF-β pathway	T038	UMLS:C1155363
27819344	990	998	SP600125	T103	UMLS:C0968383
27819344	1003	1010	PD98059	T103	UMLS:C0298346
27819344	1021	1031	inhibitors	T103	UMLS:C0243077
27819344	1035	1045	JNK kinase	T103	UMLS:C0291988
27819344	1050	1060	ERK kinase	T103	UMLS:C0600388
27819344	1088	1091	SL4	T103	UMLS:C4278992
27819344	1102	1119	G2/M phase arrest	T038	UMLS:C1517345
27819344	1124	1136	upregulation	T038	UMLS:C0041904
27819344	1140	1143	p21	T103	UMLS:C0288472
27819344	1158	1161	SL4	T103	UMLS:C4278992
27819344	1177	1183	growth	T038	UMLS:C0007595
27819344	1199	1212	breast tumors	T038	UMLS:C1458155
27819344	1216	1225	nude mice	T204	UMLS:C0025932
27819344	1234	1246	upregulation	T038	UMLS:C0041904
27819344	1250	1253	p21	T103	UMLS:C0288472
27819344	1258	1272	downregulation	T038	UMLS:C0013081
27819344	1276	1282	cdc25C	T103	UMLS:C0213045
27819344	1343	1351	findings	T033	UMLS:C0243095
27819344	1387	1390	SL4	T103	UMLS:C4278992
27819344	1402	1440	multi-target anti-tumor drug candidate	T103	UMLS:C0003392